{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:27:45Z","timestamp":1794302865562,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ajo.2026.01.029","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:12:26Z","timestamp":1769731946000},"page":"318-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma"],"prefix":"10.1016","volume":"285","author":[{"given":"Daniela","family":"Vaisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Pe\u2019er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-0906","authenticated-orcid":false,"given":"Maya","family":"Eiger-Moscovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Marims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3688-8676","authenticated-orcid":false,"given":"Shahar","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100281","article-title":"A multicenter study validates the WHO 2022 classification for conjunctival melanocytic intraepithelial lesions with clinical and prognostic relevance","volume":"104","author":"Mudhar","year":"2024","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0046-8177(85)80061-7","article-title":"Primary acquired melanosis of the conjunctiva","volume":"16","author":"Folberg","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajo.2026.01.029_bib0003","first-page":"61","article-title":"Primary acquired melanosis of the conjunctiva: experience with 311 eyes","volume":"105","author":"Shields","year":"2007","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"8","key":"10.1016\/j.ajo.2026.01.029_bib0004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaophthalmol.2019.1640","article-title":"Multicenter, international assessment of the eighth edition of the American Joint Committee on cancer Cancer Staging Manual for conjunctival melanoma","volume":"137","author":"Jain","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.01.029_bib0005","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan lecture","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.029_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00002341-199805000-00012","article-title":"Surgical management of circumscribed conjunctival melanomas","volume":"14","author":"Shields","year":"1998","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1442-6404.2002.00490.x","article-title":"Clinical aspects of conjunctival melanoma","volume":"30","author":"Layton","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.01.029_bib0008","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/eye.2008.154","article-title":"An audit of conjunctival melanoma treatment in Liverpool","volume":"23","author":"Damato","year":"2009","journal-title":"Eye (Lond)"},{"issue":"12","key":"10.1016\/j.ajo.2026.01.029_bib0009","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.4103\/ijo.IJO_2040_19","article-title":"Tumors of the conjunctiva and cornea","volume":"67","author":"Shields","year":"2019","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2016.06.001","article-title":"Advances in the management of conjunctival melanoma","volume":"62","author":"Vora","year":"2017","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.029_bib0011","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-200666030-00005","article-title":"Mitomycin: clinical applications in ophthalmic practice","volume":"66","author":"Abraham","year":"2006","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ajo.2026.01.029_bib0012","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications","volume":"94","author":"Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.029_bib0013","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/OPTH.S1606","article-title":"Topical treatment options for conjunctival neoplasms","volume":"2","author":"Kim","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0014","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41433-020-0879-z","article-title":"Management of conjunctival melanoma with local excision and adjuvant brachytherapy","volume":"35","author":"Brouwer","year":"2021","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ajo.2026.01.029_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-9071.2010.02469.x","article-title":"Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma","volume":"39","author":"Karim","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.01.029_bib0016","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archopht.1996.01100140461020","article-title":"Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia","volume":"114","author":"Frucht-Pery","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ajo.2004.08.065","article-title":"The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C","volume":"139","author":"Pe\u2019er","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0018","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00347-005-1249-8","article-title":"[Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface]","volume":"103","author":"Fuchsluger","year":"2006","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1016\/j.ajo.2026.01.029_bib0019","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2004.01.034","article-title":"Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b","volume":"111","author":"Boehm","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00417-009-1189-0","article-title":"Interferon alpha for the treatment of melanocytic conjunctival lesions","volume":"248","author":"Herold","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.01.029_bib0021","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.2013.0084","article-title":"Application of interferon alpha 2b in conjunctival intraepithelial neoplasia: predictors and prognostic factors","volume":"30","author":"Mu\u00f1oz de Escalona Rojas","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2026.01.029_bib0022","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","article-title":"Interferon alpha 2a and 2b in ophthalmology: a review","volume":"39","author":"Lewczuk","year":"2019","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.01.029_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.optm.2006.10.017","article-title":"Topical interferon alpha 2 beta therapy in the management of conjunctival papilloma","volume":"78","author":"Falco","year":"2007","journal-title":"Optometry"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.08.027","article-title":"Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex","volume":"145","author":"Finger","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.01.029_bib0026","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1006\/jmbi.1997.1396","article-title":"The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution","volume":"274","author":"Klaus","year":"1997","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0027","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12010-018-2908-y","article-title":"Molecular and biological characterization of a prepared recombinant human interferon alpha 2b isoform","volume":"188","author":"Shaaban","year":"2019","journal-title":"Appl Biochem Biotechnol"},{"issue":"11","key":"10.1016\/j.ajo.2026.01.029_bib0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.oftal.2017.03.006","article-title":"Interferon alpha-2a as alternative treatment for conjunctival squamous cell carcinoma","volume":"92","author":"Cruzado-S\u00e1nchez","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"03","key":"10.1016\/j.ajo.2026.01.029_bib0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4236\/ojoph.2015.53014","article-title":"Treatment of conjunctival malignant melanoma with topical interferon alpha-2a","volume":"05","author":"Salihu","year":"2015","journal-title":"Open J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/eye.2017.196","article-title":"Immunoreduction of ocular surface tumours with intralesional interferon alpha-2a","volume":"32","author":"Kim","year":"2018","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.ajo.2026.01.029_bib0031","first-page":"121","article-title":"The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis","volume":"10","author":"Alavian","year":"2010","journal-title":"Hepat Mon"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.029_bib0032","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2009.10.020","article-title":"PEG IFN alfa-2a vs. alfa-2b: and the winner is \u2026?","volume":"52","author":"Crax\u00ec","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajo.2026.01.029_bib0033","first-page":"283","article-title":"Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese interferon database","volume":"9","author":"Sato","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"1 suppl 1","key":"10.1016\/j.ajo.2026.01.029_bib0034","first-page":"9","article-title":"Safety profile of interferon-alpha therapy","volume":"25","author":"Weiss","year":"1998","journal-title":"Semin Oncol"},{"issue":"3 suppl 7","key":"10.1016\/j.ajo.2026.01.029_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.33078","article-title":"Cancer immunotherapy: the interferon-alpha experience","volume":"29","author":"Kirkwood","year":"2002","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.ajo.2026.01.029_bib0036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00063030-200216050-00004","article-title":"Potential of interferon-alpha in solid tumours: part 2","volume":"16","author":"Santhanam","year":"2002","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.ajo.2026.01.029_bib0037","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1016\/j.ajo.2026.07.024","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000}},{"DOI":"10.1016\/j.ajo.2026.07.024","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:25:50Z","timestamp":1782116750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S0002939426000425"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.029","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}